Frank’s 15 years on a corporate global safety board (9 years as chair) and 7 years as Chief Safety Officer for GlaxoSmithKline (responsible for >800 products in 100+ countries) has provided an extensive background in safety methodology in all therapeutic areas across pharmaceuticals, vaccines, and consumer health.    He has expertise in safety both for clinical trial and marketed product signal detection methodology, thorough knowledge of international safety regulations, and organizational safety governance.   Frank can help institutions of all types and sizes in reviewing both individual product safety issues as well as how to improve the effectiveness of a pharmacovigilance function.